• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

L-寡核苷酸的临床潜力:挑战与机遇。

The clinical potential of l-oligonucleotides: challenges and opportunities.

作者信息

Shearer Victoria, Yu Chen-Hsu, Han Xuan, Sczepanski Jonathan T

机构信息

Department of Chemistry, Texas A&M University College Station Texas 77843 USA

出版信息

Chem Sci. 2024 Oct 21;15(44):18239-58. doi: 10.1039/d4sc05157b.

DOI:10.1039/d4sc05157b
PMID:39479156
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11514577/
Abstract

Chemically modified nucleotides are central to the development of biostable research tools and oligonucleotide therapeutics. In this context, l-oligonucleotides, the synthetic enantiomer of native d-nucleic acids, hold great promise. As enantiomers, l-oligonucleotides share the same physical and chemical properties as their native counterparts, yet their inverted l-(deoxy)ribose sugars afford them orthogonality towards the stereospecific environment of biology. Notably, l-oligonucleotides are highly resistant to degradation by cellular nucleases, providing them with superior biostability. As a result, l-oligonucleotides are being increasingly utilized for the development of diverse biomedical technologies, including molecular imaging tools, diagnostic biosensors, and aptamer-based therapeutics. Herein, we present recent such examples that highlight the clinical potential of l-oligonucleotides. Additionally, we provide our perspective on the remaining challenges and practical considerations currently associated with the use of l-oligonucleotides and explore potential solutions that will lead to the broader adoption of l-oligonucleotides in clinical applications.

摘要

化学修饰的核苷酸是生物稳定研究工具和寡核苷酸疗法发展的核心。在这种背景下,L-寡核苷酸作为天然D-核酸的合成对映体,具有巨大的潜力。作为对映体,L-寡核苷酸与其天然对应物具有相同的物理和化学性质,但其倒置的L-(脱氧)核糖糖使其在生物学的立体特异性环境中具有正交性。值得注意的是,L-寡核苷酸对细胞核酸酶的降解具有高度抗性,赋予它们卓越的生物稳定性。因此,L-寡核苷酸正越来越多地用于多种生物医学技术的开发,包括分子成像工具、诊断生物传感器和基于适体的疗法。在此,我们展示了最近的此类实例,突出了L-寡核苷酸的临床潜力。此外,我们阐述了目前与使用L-寡核苷酸相关的剩余挑战和实际考量,并探索了可能促成L-寡核苷酸在临床应用中更广泛采用的潜在解决方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/bbd477a173bf/d4sc05157b-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/1832fa1a2448/d4sc05157b-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/d9b0a1e4f7fb/d4sc05157b-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/df3ec246791a/d4sc05157b-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/cb9fda8cec7c/d4sc05157b-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/bbd477a173bf/d4sc05157b-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/1832fa1a2448/d4sc05157b-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/d9b0a1e4f7fb/d4sc05157b-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/df3ec246791a/d4sc05157b-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/cb9fda8cec7c/d4sc05157b-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/084b/11559405/bbd477a173bf/d4sc05157b-f5.jpg

相似文献

1
The clinical potential of l-oligonucleotides: challenges and opportunities.L-寡核苷酸的临床潜力:挑战与机遇。
Chem Sci. 2024 Oct 21;15(44):18239-58. doi: 10.1039/d4sc05157b.
2
Mirror-Image Oligonucleotides: History and Emerging Applications.镜像寡核苷酸:历史与新兴应用。
Chemistry. 2019 Jun 18;25(34):7981-7990. doi: 10.1002/chem.201900149. Epub 2019 Apr 26.
3
Heterochiral Nucleic Acid Circuits.异手性核酸电路
Emerg Top Life Sci. 2019 Nov;3(5):501-506. doi: 10.1042/etls20190102. Epub 2019 Aug 28.
4
Scaffolding along nucleic acid duplexes using 2'-amino-locked nucleic acids.使用 2'-氨基锁核酸在核酸双链体上搭建支架。
Acc Chem Res. 2014 Jun 17;47(6):1768-77. doi: 10.1021/ar500014g. Epub 2014 Apr 21.
5
Re-Engineering RNA Molecules into Therapeutic Agents.将 RNA 分子重建成治疗剂。
Acc Chem Res. 2019 Apr 16;52(4):1036-1047. doi: 10.1021/acs.accounts.8b00650. Epub 2019 Mar 26.
6
Delivery of oligonucleotide-based therapeutics: challenges and opportunities.寡核苷酸类治疗药物的递送:挑战与机遇。
EMBO Mol Med. 2021 Apr 9;13(4):e13243. doi: 10.15252/emmm.202013243. Epub 2021 Apr 6.
7
The influence of chirality on the behavior of oligonucleotides inside cells: revealing the potent cytotoxicity of G-rich l-RNA.手性对细胞内寡核苷酸行为的影响:揭示富含鸟嘌呤的 l - RNA 的强细胞毒性
Chem Sci. 2022 Dec 30;14(5):1145-1154. doi: 10.1039/d2sc05511b. eCollection 2023 Feb 1.
8
Small non-coding RNA therapeutics for cardiovascular disease.小非编码 RNA 治疗心血管疾病。
Eur Heart J. 2022 Nov 14;43(43):4548-4561. doi: 10.1093/eurheartj/ehac463.
9
Liver as a target for oligonucleotide therapeutics.肝脏作为寡核苷酸治疗药物的靶标。
J Hepatol. 2013 Dec;59(6):1354-9. doi: 10.1016/j.jhep.2013.05.045. Epub 2013 Jun 12.
10
Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.寡核苷酸适配体及其作为治疗剂应用的最新研究进展。
3 Biotech. 2020 Dec;10(12):551. doi: 10.1007/s13205-020-02546-1. Epub 2020 Nov 24.

引用本文的文献

1
Sequencing of d/l-DNA and XNA by Templated-Synthesis.通过模板合成对d/l-DNA和XNA进行测序。
J Am Chem Soc. 2025 Feb 19;147(7):6288-6296. doi: 10.1021/jacs.5c00708. Epub 2025 Feb 10.

本文引用的文献

1
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.基于 L-RNA 适体的 CXCL12 抑制联合放疗治疗新诊断的胶质母细胞瘤:GLORIA 试验的 I/II 期剂量递增研究。
Nat Commun. 2024 May 28;15(1):4210. doi: 10.1038/s41467-024-48416-9.
2
Cell-resistant wavelength-shifting molecular beacons made of L-DNA and a clickable L-configured uridine.由 L-DNA 和可点击的 L 构型尿嘧啶制成的抗细胞波长转换分子信标。
Org Biomol Chem. 2024 Jun 5;22(22):4568-4573. doi: 10.1039/d4ob00692e.
3
A Review on Commercial Oligonucleotide Drug Products.
商业寡核苷酸药物产品述评。
J Pharm Sci. 2024 Jul;113(7):1749-1768. doi: 10.1016/j.xphs.2024.04.021. Epub 2024 Apr 26.
4
Implementing L-DNA analogs as mirrors of PCR reactant hybridization state: theoretical and practical guidelines for PCR cycle control.实施 L-DNA 类似物作为 PCR 反应物杂交状态的镜像:PCR 循环控制的理论和实践指南。
Anal Methods. 2024 May 9;16(18):2840-2849. doi: 10.1039/d4ay00083h.
5
2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.2023年美国食品药品监督管理局肽和寡核苷酸采集活动
Pharmaceuticals (Basel). 2024 Feb 13;17(2):243. doi: 10.3390/ph17020243.
6
Profiling the interactome of oligonucleotide drugs by proximity biotinylation.通过邻近生物素化技术对寡核苷酸药物的相互作用组进行分析。
Nat Chem Biol. 2024 May;20(5):555-565. doi: 10.1038/s41589-023-01530-z. Epub 2024 Jan 17.
7
Heterochiral modifications enhance robustness and function of DNA in living human cells.手性修饰增强了活人体细胞中 DNA 的稳定性和功能。
Chembiochem. 2024 Mar 1;25(5):e202300755. doi: 10.1002/cbic.202300755. Epub 2024 Feb 12.
8
Rational Design of L-RNA Aptamer-Peptide Conjugate for Efficient Cell Uptake and G-quadruplex-Mediated Gene Control.L-RNA 适体-肽缀合物的合理设计用于高效细胞摄取和 G-四链体介导的基因控制。
Angew Chem Int Ed Engl. 2024 Feb 26;63(9):e202310798. doi: 10.1002/anie.202310798. Epub 2024 Jan 22.
9
Selective targeting of parallel G-quadruplex structure using L-RNA aptamer.使用 L-RNA 适体选择性靶向平行 G-四链体结构。
Nucleic Acids Res. 2023 Nov 27;51(21):11439-11452. doi: 10.1093/nar/gkad900.
10
FDA approves second RNA aptamer.美国食品药品监督管理局批准第二种RNA适配体。
Nat Rev Drug Discov. 2023 Oct;22(10):774. doi: 10.1038/d41573-023-00148-z.